CoChat

Inflammation in Alzheimer’s disease: insights from immunotherapy

Schott, Jonathan M., Revesz, Tamas · 2013 · Brain
Cited by 50

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

More than 20 years after its initial formulation, the amyloid cascade hypothesis—which postulates that build-up of toxic amyloid-β species initiates a series of events that culminates in neurodegeneration and symptoms (Hardy and Higgins, 1992)—continues to dominate thinking on the pathogenesis of Alzheimer’s disease. Although the exact sequence of events linking amyloid-β accumulation to aggregation of hyperphosphorylated tau in different neuronal compartments, neuronal loss, synaptic dysfunction and symptoms remains unknown, there is now a substantial body of evidence implicating neuroinflammation in the pathogenesis of Alzheimer’s disease. Thus activated microglia accumulate around amyloid plaques both in the brains of individuals with Alzheimer’s disease and in transgenic mice, and have been implicated in promoting neurodegeneration (Akiyama et al., 2000). Imaging studies using the 11C-R-PK11195 PET ligand provide evidence that activated microglial accumulate in the vicinity of amyloid plaque pathology, and that activated microglial burden correlates with declining cognition (Edison et al., 2008). Genome-wide association studies have identified a number of risk variants for Alzheimer’s disease implicated in inflammatory responses (Bettens et al., 2013); exome sequencing has revealed polymorphisms in the microglial receptor TREM2 gene as a rare but significant risk for Alzheimer’s disease (Guerreiro et al., 2013; Jonsson et al., 2013); and recently, the CD33 risk allele has been shown to inhibit microglial clearance of amyloid-β (Bradshaw et al., 2013; Griciuc et al., 2013). Finally, an integrative network-based genetic analysis of Alzheimer’s disease brain has implicated disturbance in immune/microglial networks in the pathogenesis of the disease (Zhang et al., 2013). If inflammation, and microglial activation in particular, are core features of Alzheimer’s disease, the exact mechanisms involved, and the roles of the different inflammatory components are far less clear. Microglia—the predominant macrophage species within the brain—can express different cell-surface receptors and change morphology in response to changes in local environment thus becoming ‘activated’ in numerous ways (Perry et al., 2010). It is likely that in the Alzheimer’s disease brain some activated microglial species may, in certain circumstances, adopt a proinflammatory profile with deleterious effects, promoting neuronal and synaptic damage. Conversely, a microglial reaction initiated in response to, and promoting clearance of toxic amyloid-β species may confer protection. Given evidence that reductions in the rate of clearance of amyloid-β1–42 are seen in sporadic Alzheimer’s disease (Mawuenyega et al., 2010), it may be that subtle alterations in normal inflammatory-mediated clearance of fibrillar or perhaps oligomeric amyloid-β (Frenkel et al., 2013) play important roles in the earliest stages of Alzheimer’s disease pathogenesis. Targeting the inflammatory cascade in Alzheimer’s disease either to attenuate harmful effects or promote clearance of abnormal proteins is an attractive therapeutic option. To date, clinical trials of ‘anti-inflammatory’ drugs including non-steroidals and aspirin have yet to show definite benefits in Alzheimer’s disease (Jaturapatporn et al., 2012). After the remarkable demonstration that peripheral, active vaccination against amyloid-β1–42 leads to clearance of brain amyloid from the brains of transgenic mice carrying human Alzheimer’s disease mutations (Schenk et al., 1999) immunotherapy-based approaches aimed at promoting amyloid clearance have dominated attempts to modify the course of human Alzheimer’s disease over the last decade or so. The first such study in man (AN1792) was halted after 6% of those on active therapy developed significant brain inflammation (Gilman et al., 2005). Subsequently, none of a number of passive vaccination studies using a number of different agents all targeting slightly different parts of the amyloid-β1–42 protein has succeeded in reaching their primary, clinical end-points in pivotal trials (reviewed in Karran, 2012). Importantly, however, there is considerable evidence that these approaches are having immune/inflammatory-mediated effects within the human brain. Aside from the meningoencephalitis that complicated the original AN1792 trial (Fox et al., 2005), in several studies, and particularly in ApoE ε4 carriers, immunotherapy has been associated with ‘amyloid-related imaging abnormalities’—often asymptomatic and usually mild and reversible oedema/effusions (ARIA-E) or haemosiderin deposition (ARIA-H), that may reflect immune-related flux of amyloid pathology in/out of vessels (Sperling et al., 2011). Amyloid-β vaccination has been shown to alter Alzheimer’s disease biomarkers including levels of CSF tau (Blennow et al., 2012). Finally, significant reduction in brain amyloid-β pathology has been demonstrated in the few treated patients that have thus far come to post

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awt231

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 50

Metadata

Authors
Schott, J. M., & Revesz, T.
Venue
Brain
Published
2013-08-26
Volume
136
Issue
9
Pages
2654-2656
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W1990992163
Cited by
50
References
17
FWCI
4.50
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.